Should clinical studies involving "regenerative injection therapy," strive to incorporate a triad of outcome measures instead of only including clinical outcome measures?
Virginia Commonwealth University, Department of Physical Medicine and Rehabilitation, United States. Electronic address: Jason.Tucker@va.gov.
J D
JD
Tucker
The Kaplan Center, McLean, VA, United States.
J J
JJ
Ericksen
Virginia Commonwealth University and Hunter Holmes McGuire VA Medical Center, Department of Physical Medicine and Rehabilitation, United States.
L L
LL
Goetz
Virginia Commonwealth University, Department of Pathology, United States.
L W
LW
Elmore
D001688:Biological Products / Q000008:administration & dosage* / Q000494:pharmacology; D015415:Biomarkers / Q000097:blood; D002358:Cartilage, Articular / Q000187:drug effects / Q000503:physiopathology; D002986:Clinical Trials as Topic; D006801:Humans; D007270:Injections, Intra-Articular; D007279:Injections, Subcutaneous; D045164:Mesenchymal Stem Cell Transplantation / Q000379:methods*; D059630:Mesenchymal Stem Cells; D010003:Osteoarthritis / Q000175:diagnosis / Q000628:therapy*; D017063:Outcome Assessment, Health Care; D053657:Platelet-Rich Plasma; D044968:Regenerative Medicine / Q000379:methods*; D016896:Treatment Outcome
D001688:Biological Products; D015415:Biomarkers
Biological mechanism of action; Biomarkers; Growth Factors; Mesenchymal Stem Cells; Platelet rich plasma; Regenerative injection therapy